Skip to main content

Table 2 Efficacy of rituximab on clinical and biologic parameters of nine SSc patients treated with anti-CD20 during the follow up

From: B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial

  Baseline After 3
Months
After 6
Months
After 12
months*
After 18
months**
After 24
months***
After 36
months****
Rodnan skin score        
(mean (SD)) 21.1 (9.0) 15.2 (6.0) 12.0 (6.1) 7.0 (4.0) 7.0 (3.5) 5.0 (2.0) 4.0 (1.4)
(median (range)) 19.0 (7-36) 15.0 (5-27) 10.0 (4-26) 8.0 (3-14) 7.5 (3-10) 5.0 (3-7) 4.0 (3-5)
Disease activity index        
(mean (SD)) 4.8 (1.3) 2.0 (1.2) 1.2 (1.2) 0.9 (1.0) 1.0 (1.3) 1.3 (1.4) 1.7 (1.8)
(median (range)) 4.5 (3.5-7.0) 2.0 (0.5-3.5) 0.5 (0.5-3.5) 0.5 (0.5-3.0) 0.5 (0.5-3.0) 0.5 (0.5-3.0) 1.7 (0.5-3.0)
Disease severity index        
(mean (SD)) 10.5 (3.2) 8.3 (2.9) 7.2 (2.8) 6.2 (2.8) 6.7 (2.2) 7.7 (1.5) 8.5 (0.7)
(median (range)) 11.0 (6-15) 7.0 (4-13) 6.0 (4-11) 6.0 (3-9) 7.0 (4-9) 8.0 (6-9) 8.5 (8-9)
HAQ        
(mean (SD)) 0.9 (0.7) 0.5 (0.5) 0.4 (0.5) 0.3 (0.7) 0.3 (0.6) 0.3 (0.6) 0.6 (0.6)
(median (range)) 0.8 (0.1-2.4) 0.4 (0-1.6) 0.2 (0-1.5) 0 (0-1.5) 0 (0-1.2) 0 (0-1.1) 0 (0-1.3)
GH (mean (SD)) 59.4 (20.9) 74.4 (16.5) 82.8 (16.6) 86.0 (10.8) 82.5 (21.8) 82.5 (17.7) 82.5 (17.7)
(median (range)) 60.0 (30-85) 80.0 (50-95) 90.0 (50-95) 90.0 (70-95) 92.5 (50-95) 82.5 (70-95) 82.5 (70-95)
Blood CD20%        
(mean (SD)) 6.8 (3.9) 0.7 (1.5) 1.7 (2.4) 3.0 (2.7) 2.0 (1.6) 1.0 (1.5) 3.0 (3.3)
(median (range)) 6.0 (2.5-14.7) 0.1 (0.1-4.6) 1.0 (0.1-7.0) 4.0 (0.3-7.0) 2.0 (0.2-3.0) 1.0 (0.2-3.0) 3.0 (0.3-5.0)
IgG mg/ml        
(mean (SD)) 1055 (233) 1001 (191) 1021 (158) 1028 (46.6) 946.2 (178) 944 (315) 951 (69)
(median (range)) 1140 (729-1340) 932 (884-1440) 1030 (802-1220) 1005 (1000-1110) 938 (738-1170) 896 (656-1280) 951 (902-1000)
IgA mg/ml        
(mean (SD)) 184.0 (44.4) 174.5 (39.2) 177.8 (63.5) 179.4 (69.8) 152.5 (59.9) 139.0 (67.5) 100.0 (24.0)
(median (range)) 183.5 (119-249) 183.5 (119-262) 200.0 (75-262) 168.5 (93-281) 154.0 (79-222) 136.0 (73-208) 100.0 (83-117)
IgM mg/ml        
(mean (SD)) 133.7 (21.7) 86.0 (12.8) 90.9 (28.9) 83.0 (18.7) 61.5 (6.7) 43.3 (10.6) 71.0 (1.4)
(median (range)) 132.5 (95-157) 91.0 (56-136) 96.0 (40-136) 73.0 (64-105) 61.5 (54-69) 45.0 (32-53) 71.0 (70-72)
BAFF pg/ml        
(mean (SD)) 1233.5 (683.3) 1719.4 (1264.3) 3257.8 (1571.8) 2057.0 (912.5) 2988.0 (1804) 3520.0 (1999) 3608.0 (2824)
(median (range)) 875.6 (683-2601) 1008.6 (356-4038) 3141.8 (723-6682) 1580.6 (1321.6-3280) 2406.2 (1534-5605) 3224.8 (1684-5651) 3608.0 (1610-5605)
IL6 pg/ml        
(mean (SD)) 3.7 (5.3) 1.0 (1.2) 0.6 (0.9) 0.4 (0.4) 1.2 (2.0) 0.1 (0.1) 0.1 (0.1)
(median (range)) 1.7 (0.1-16.9) 0.1 (0.1-3.6) 0.1 (0.1-2.8) 0.4 (0.1-0.8) 0.25 (0.1-4.2 0.1 (0.1-0.1) 0.1 (0.1-0.1)
  1. Clinical and biological parameters of nine SSc patients treated with anti-CD20 at baseline, after 3, 6, 12, 18, 24 and 36 months. The values are indicated as the mean (SD) and median (range). All patients had trunk skin involvement.
  2. *Five SSc patients reached 12 months of follow up. **Four SSc patients reached 18 months of follow up. ***Three SSc patients reached 24 months of follow up. *****Two patients reached 36 months of follow up.
  3. BAFF, B-cell activating factor; GH, Global Health Status; HAQ, Health Assessment Questionnarie; Ig, immunoglobulin; SD, standard deviation; SSc, systemic sclerosis.